Barclays
CNSP icon

Barclays’s CNS Pharmaceuticals CNSP Stock Holding History

Barclays’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91 Buy
+19
New +$80 ﹤0.01% 5201

Other funds holding CNSP

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Barclays's CNSP Position: Q2 2026 in Review

Barclays opened a new position in CNS Pharmaceuticals (CNSP) in Q2 2026: 19 shares worth $91. The stake represents ﹤0.01% of the portfolio and ranks #5201 among its holdings.

11 funds tracked by Wall St. Rank hold CNSP as of Q2 2026.

  • Barclays held 19 shares of CNS Pharmaceuticals worth $91 as of Q2 2026.
  • CNS Pharmaceuticals was a new Barclays position in Q2 2026.
  • CNS Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5201 holding.
  • 11 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.